Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
biotech
boston blog main
clinical trials
life sciences
national blog main
2
×
san francisco blog main
2
×
ame cloud ventures
american diabetes association
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boston
boston top stories
clostridium difficile
colleen cutcliffe
computational biology
diabetes type 2
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
fda
gene therapy
inflammatory bowel disease
investing
joshua brumm
kaleido biosciences
khosla ventures
mayo foundation
medical foods
metformin
microbiome
muscular dystrophy
myotonic dystrophy type 1
national top stories
new york blog main
rare disease drugs
romesh subramanian
san diego blog main
What
eyes
2
×
ago
available
balance
biome
biotechs
blood
considering
data
diabetes
diseases
drug
dyne
early
expected
experimental
food
genetic
having
healthy
hormone
humans
include
intended
ipo
ipos
launch
leads
levels
long
medical
medicines
muscle
pills
rare
reach
restore
shots
sugar
therapeutics
Language
unset
Current search:
eyes
×
photo
×
" san francisco blog main "
×
" national blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
With $35M, Whole Biome Eyes 2020 Launch of Medical Food for Diabetes